Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Хронический эндометрит: современные взгляды на проблему
Хронический эндометрит: современные взгляды на проблему
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Корсак, В.С., Забелкина О.В., Исакова Э.В. Исследование эндометрия у пациенток с трубно-перитонеальным бесплодием на этапе подготовки к ЭКО. Проблемы репродукции. 2005; 2: 39–42.
2. Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2000.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. М.: МИА, 2002.
4. Buckley CH, Fox H. Biopsy pathology of the endometrium. NY: Arnold, 2002.
5. Шуршалина А.В. Хронический эндометрит. Автореф. дис. ... д-ра мед. наук. М., 2007.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report (MMWR) 2010; 59 (RR-12): 1–114.
7. Демидов В.Н., Гус А.И. Эхография органов малого таза у женщин. Вып. III. Патология полости матки и эндометрия. ВМК: практ. пособие. М., 2000; с. 16–36.
8. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3–25.
9. Novak ER,Woodruff JD. Gynecologic and obstetric pathology. Philadelphia 1999; 241–5.
10. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
11. Стругацкий В.М., Силантьева Е.С. Акуш. и гинекол. 2002; 6: 51–3.
12. Haggerty CL, Ness RB. Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl) 2008; 4 (4): 383–97.
13. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19 (1): 53–9.
14. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 2008; 3 (11): e3618.
15. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Bjog 2010; 117 (3): 361–4.
16. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert review of anti-infective therapy 2011; 9 (1): 61–70.
17. Bhengraj AR, Vardhan H, Srivastava P, Salhan S et al. Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in India. Chemotherapy 2010; 56 (5): 371–7.
18. Sternak SL, Skerk V. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas Ljek komore Zenicko-doboj kantona 2010; 7 (1): 26–31.
19. Segreti J, Kapell KS, Trenholme GM. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagnostic microbiology and infectious disease 1992; 15 (4): 371–3.
20. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica 2000; 79 (3): 234–7.
21. Oshima T, Iwadare M. Josamycin propionate. 5. Teratological studies. The Japanese journal of antibiotics 1973; 26 (2): 148–53.
22. Ikezaki S, Nishikawa A, Furukawa F et al. A 13-week subchronic toxicity study of josamycin in F344 rats. Eisei Shikenjo Hokoku 1995; (113): 44–50.
23. Miura M, Morino T, Endo H, Shiraiwa K et al. Comparative toxicity study of rokitamycin and josamycin in rats. Jpn J Antibiot 1987; 40 (3): 588–601.
24. Kuriaki K, Miki H, Sejima Y, Shibata M et al. New antibiotics, Josamycin. V. Studies on toxicity of Josamycin. Jpn J Antibiot 1969; 22 (3): 219–25.
25. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy – 15 years experience of ENTIS. Reproductive toxicology. Elmsford. NY, 2005; 20 (3): 331–43.
2. Сидельникова В.М. Привычная потеря беременности. М.: Триада-Х, 2000.
3. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология: руководство для врачей. М.: МИА, 2002.
4. Buckley CH, Fox H. Biopsy pathology of the endometrium. NY: Arnold, 2002.
5. Шуршалина А.В. Хронический эндометрит. Автореф. дис. ... д-ра мед. наук. М., 2007.
6. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morbidity and Mortality Weekly Report (MMWR) 2010; 59 (RR-12): 1–114.
7. Демидов В.Н., Гус А.И. Эхография органов малого таза у женщин. Вып. III. Патология полости матки и эндометрия. ВМК: практ. пособие. М., 2000; с. 16–36.
8. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3–25.
9. Novak ER,Woodruff JD. Gynecologic and obstetric pathology. Philadelphia 1999; 241–5.
10. Ness RB, Soper DE, Holley RL. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: Results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002; 186 (5): 929–37.
11. Стругацкий В.М., Силантьева Е.С. Акуш. и гинекол. 2002; 6: 51–3.
12. Haggerty CL, Ness RB. Diagnosis and treatment of pelvic inflammatory disease. Womens Health (Lond Engl) 2008; 4 (4): 383–97.
13. Morikawa K, Zhang J, Nonaka M, Morikawa S. Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents 2002; 19 (1): 53–9.
14. Bradshaw CS, Chen MY, Fairley CK. Persistence of Mycoplasma genitalium following azithromycin therapy. PLoS ONE 2008; 3 (11): e3618.
15. Bjartling C, Osser S, Persson K. The association between Mycoplasma genitalium and pelvic inflammatory disease after termination of pregnancy. Bjog 2010; 117 (3): 361–4.
16. Jaiyeoba O, Lazenby G, Soper DE. Recommendations and rationale for the treatment of pelvic inflammatory disease. Expert review of anti-infective therapy 2011; 9 (1): 61–70.
17. Bhengraj AR, Vardhan H, Srivastava P, Salhan S et al. Decreased Susceptibility to Azithromycin and Doxycycline in Clinical Isolates of Chlamydia trachomatis Obtained from Recurrently Infected Female Patients in India. Chemotherapy 2010; 56 (5): 371–7.
18. Sternak SL, Skerk V. [Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice]. Med Glas Ljek komore Zenicko-doboj kantona 2010; 7 (1): 26–31.
19. Segreti J, Kapell KS, Trenholme GM. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis. Diagnostic microbiology and infectious disease 1992; 15 (4): 371–3.
20. Czeizel AE, Rockenbauer M, Olsen J, Sorensen HT. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta obstetricia et gynecologica Scandinavica 2000; 79 (3): 234–7.
21. Oshima T, Iwadare M. Josamycin propionate. 5. Teratological studies. The Japanese journal of antibiotics 1973; 26 (2): 148–53.
22. Ikezaki S, Nishikawa A, Furukawa F et al. A 13-week subchronic toxicity study of josamycin in F344 rats. Eisei Shikenjo Hokoku 1995; (113): 44–50.
23. Miura M, Morino T, Endo H, Shiraiwa K et al. Comparative toxicity study of rokitamycin and josamycin in rats. Jpn J Antibiot 1987; 40 (3): 588–601.
24. Kuriaki K, Miki H, Sejima Y, Shibata M et al. New antibiotics, Josamycin. V. Studies on toxicity of Josamycin. Jpn J Antibiot 1969; 22 (3): 219–25.
25. Schaefer C, Hannemann D, Meister R. Post-marketing surveillance system for drugs in pregnancy – 15 years experience of ENTIS. Reproductive toxicology. Elmsford. NY, 2005; 20 (3): 331–43.
Авторы
А.В.Шуршалина
Американский медицинский центр, Москва
Американский медицинский центр, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.